Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Jiangya Pian (Compound Antihypertensive Tablet) is a traditional fixed-dose combination (FDC) medication widely utilized in China for the management of mild to moderate hypertension. The formulation typically integrates several active pharmaceutical ingredients with distinct mechanisms: reserpine (a vesicular monoamine transporter inhibitor that depletes catecholamines), dihydralazine (a direct-acting peripheral vasodilator), and hydrochlorothiazide (a thiazide diuretic that reduces blood volume). It also frequently contains promethazine for its mild sedative effects and various vitamins (B1, B6) and minerals (potassium, magnesium) to mitigate potential side effects and support metabolic health. Developed and utilized extensively within the Chinese healthcare system, particularly in community settings, it offers a cost-effective strategy for long-term blood pressure management. It has been the subject of large-scale clinical trials, such as those conducted by Fuwai Hospital, to evaluate its efficacy and compliance in primary care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang jiangya pian.